Canadian Marketing and Sales Effort for Labopharm's Once-Daily Tramadol Product to Expand Sig...(tates both rapid and sustained drug rele...),Health

Date:2/1/2008

tates both rapid and sustained drug release, maintaining therapeutic blood levels of tramadol for a full 24-hour period. Tridural(TM) offers physicians and patients greater treatment flexibility based on its relatively rapid two-day titration schedule, which could help patients reach their optimum daily dose faster than any other approved once-daily tramadol product and quickly achieve effective pain relief. In addition, Tridural(TM) has a demonstrated safety profile based on clinical trial experience of more than 2,400 patients globally and almost two years of commercial experience.

About the Global Commercialization Program for Labopharm's Once-Daily

Tramadol Product

Under its global commercialization program, Labopharm's once-daily tramadol product has been launched in 10 countries, including the five largest markets in Europe and Canada, and is approved in 15 other countries. Including those countries in which its product has been launched, Labopharm has licensing and distributions in place for more than 50 markets worldwide.

About Labopharm Inc.

Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily formulation of tramadol, is being commercially launched in key markets globally. The Company also has a robust pipeline of follow-on products in both pre-clinical and clinical development. Labopharm's vision is to become a fully integrated, international, specialty pharmaceutical company with the capability to internally develop and commercialize its own products. For more information, please visit http://www.labopharm.com.

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events coul
'/>"/>

SOURCE Labopharm Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine news :

1. New prion protein discovered by Canadian scientists may offer insight into mad cow disease
2. Ibuprofen can slow lung disease in children with cystic fibrosis, Canadian study shows
3. New Canadian study finds drug coated heart stents to be safe:
4. Canadians welcome HPV vaccine -- but not at any price
5. Mayo Clinic Calls for Thorough Review of Canadian Pacifics Acquisition of the Dakota, Minnesota & Eastern Railroad
6. Canadian Pacific and Mayo Clinic Build Understanding and Commit to Ongoing Dialogue
7. Map the Canadian Healthcare IT Market with the New HIMSS Analytics Canadian Database(SM)
8. Omnicom Acquires Leading Healthcare Marketing Communications Firm in China
9. Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
10. Crdentias VP of Marketing, Christina Hogan, Provides Exclusive Interview on Marketing Strategy
11. Fitness Champion Natalie Waples to be Spokesperson for Natural Nutrition International Direct Marketing Campaign